Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.35 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595058 | 0.86 | P2RY2 (0.47) | POLBP2RY2P2RY4P2RY6 | |
| Phosphoric Acid SCHEMBL595617 | 0.82 | TYMS (0.45) | POLBTYMSDUT | |
| SCHEMBL594778 | 0.78 | ADK (0.45) | TYMSDUT | |
| SCHEMBL594779 | 0.78 | ADK (0.45) | TYMSDUT | |
| SCHEMBL5323678 | 0.73 | P2RY14 (0.51) | P2RY2P2RY4P2RY6DUT | |
| SCHEMBL29431049 | 0.72 | DUT (0.56) | P2RY2P2RY4P2RY6DUT | |
| SCHEMBL5318914 | 0.71 | P2RY14 (0.51) | P2RY2P2RY4RNASE1P2RY6DUT | |
| Phosphoric Acid SCHEMBL595057 | 0.68 | LMNA (0.45) | POLBP2RY2P2RY4 | |
| SCHEMBL21437348 | 0.67 | POLB (0.61) | POLBRNASE1 | |
| SCHEMBL6534888 | 0.67 | POLB (0.61) | POLBRNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981078-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130004945-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | BERDIS ANTHONY J (US) | 2013-01-03 | — | — | US | disclosed |
| US-8114847-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | CASE WESTERN RESERVE UNIVERSITY | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | REV1, PCNA, DNA2 | POLB 11/4885P2RY2 4389/4885P2RY4 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.